TauRX recently announced data on their drug remberTM has shown that in 81% of users, there is been a slow down in the cognitive decline in patients with Alzheimer’s. As Fierce Biotech reported this disease has been especially difficult for researchers to find a cure. Professor Claude Wischik offers some hope saying that
"This is an unprecedented result in the treatment of Alzheimer's disease. We have demonstrated for the first time that it may be possible to arrest progression of the disease by targeting the tangles which are highly correlated with the disease."
This news comes on the heels of the announcement from Myriad Genetics who announced that they are abandoning their over $60 million effort on Flurizan which had failed in late stage trials.
No comments:
Post a Comment